Use of a glycoalkaloid composition containing at least one Z Glycoalkaloid
of formula 1: 1
wherein: either one or both of the dotted lines represents a double bond,
and the other a single bond, or both represent single bonds;
A: represents a radical selected from the following radicals of general
formulae (II) to (V): 2
each of R.sup.1 is a radical separately selected from the group consisting
of hydrogen, amino, oxo and OR.sup.4;
each of R.sup.2 is a radical separately selected from the group consisting
of hydrogen, amino and OR.sup.4;
each of R.sup.3 is a radical separately selected from the group consisting
of hydrogen, carbohydrate and a carbohydrate derivative;
"X" is a radical selected from the group comprising --CH.sub.2--, --O--
and --NH.sub.2--; and
wherein the compound includes at least one R.sup.4 group that is a
carbohydrate or a derivative such as one selected from the group
comprising glyceric aldehyde, glycerose, erythrose, threose, ribose,
arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose,
idose, galactose, talose, rhamnose, dihydroxyactone, erythrulose,
ribulose, xylulose, psicose, fructose, sorbose, tagatose, and other
hexoses, heptoses, octoses, nanoses, decoses, deoxysugars with branched
chains, (e.g. apiose, hamamelose, streptose, cordycepose, mycarose and
cladinose), compounds wherein the aldehyde, ketone or hydroxyl groups
have been substituted (e.g. N-acetyl, acetyl, methyl, replacement of
CH.sub.2OH), sugar alcohols, sugar acids, benzimidazoles, the enol salts
of the carbohydrates, saccharinic acids, sugar phosphates;
as an IL-6 antagonist.
